+1 Recommend
    • Review: found
    Is Open Access

    Review of 'Apolipoprotein C-III's role in cardiovascular diseases, a short review.'

    Apolipoprotein C-III's role in cardiovascular diseases, a short review.Crossref
    An interesting brief review regarding ApoC-III, but written in poor language and not well justified.
    Average rating:
        Rated 2 of 5.
    Level of importance:
        Rated 2 of 5.
    Level of validity:
        Rated 3 of 5.
    Level of completeness:
        Rated 2 of 5.
    Level of comprehensibility:
        Rated 1 of 5.
    Competing interests:

    Reviewed article

    • Record: found
    • Abstract: found
    • Article: found
    Is Open Access

    Apolipoprotein C-III's role in cardiovascular diseases, a short review.

    In this short review we show the important role played by apoC-III in the lipid dysregulation present in the majority of cardiovascular diseases. With emphasis on the mutations present in a minority of individuals that confer protection. With this in mind we state that apoC-III should be considered a valid target for pharmaceutical intervention and cardiovascular disease control and progression.

      Review information

      This work has been published open access under Creative Commons Attribution License CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com.


      Review text

      In this article, Dr Olteanu presents a short overview of the available literature on the role of ApoC-III in CVD. The author also offers insight in the metabolic pathways and the mutations of ApoC-III and remarks their clinical impact. It is a useful mini review, since it refers to a marker that is not measured in everyday clinical practice, but it is accompanied with significant clinical manifestations regarding CVD. However, I feel that there are several concerns that need to be taken into consideration. These are the following:

      Major Concerns
      The entire manuscript needs to be re-organized and re-written due to several serious errors in composition, syntax and grammar. Moreover, it is also recommended that it is thoroughly edited by a scientific writer/editor.
      The author concludes that ApoC-III could be a potential target for a number of novel drugs. However, drugs such as statins, fibrates, ezetimibe, etc that are reported to be related with lower levels of ApoC-III are not mentioned in the “discussion” section.
      In order to elucidate the role of ApoC-III in CVD, there are more to be mentioned than just ApoC-III mutations. There are several clinical studies that report correlation between ApoC-III and cardiovascular events which deserve to be highlighted.
      Apart from VLDL and LPL, ApoC-III also interacts with β-integrin, ICAM-I, VCAM-I. These molecules also play a significant role in CVD progression. Thus, they should not be omitted.

      Minor Concerns
      The article title could be changed to “Apolipoprotein C-III’s role in cardiovascular diseases: A brief review”.
      In “ApoC-III SUMMARY” please specify which enteric cells participate in the excretion of ApoC-III.

      Moreover, a more extensive review that sheds light on various aspects of the link between ApoC-III and CVD is the following “OOI et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science 2008;114:611-624”. Thus, it is my firm belief that it should be included in the references.


      Comment on this review